You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

How to Prescribe

A complete once-daily regimen in 2 small pills, once a day

Go To Top Close

A convenient regimen: 1 2

Once a day

No food requirements

No time-of-day restrictions

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. 1

Epivir (lamivudine) is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. 2

A Regimen with Few Drug-Drug Interactions

  • Minimal effect on metabolism via the CYP3A4 pathway
  • No known interactions with contraceptives, antihypertensives, proton pump inhibitors, statins, PDE-5 inhibitors or recreational drugs
  • DTG is contraindicated with dofetilide
  • Avoid chronic co-administration of sorbitol and similar solutions with 3TC
  • Concomitant use of 3TC with Cladribine is not recommended
  • Should not be used with any other cytidine analogs, e.g. emtricitabine
  • 3TC and high doses of co-trimoxazole for the treatment of PCP or toxoplasmosis should be avoided
  • Dose separation for antacids and supplements
  • Dose adjustment of DTG required for rifampicin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin and St John’s wort
  • Dose adjustment of metformin may be required

For further information, please see the Tivicay Summary of Product Characteristics and Epivir Summary of Product Characteristics.

Women of childbearing potential (WOCBP) should undergo pregnancy testing before initiation of dolutegravir. WOCBP who are taking dolutegravir should use effective contraception throughout treatment.1

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.